Sustained disease control in ovarian carcinosarcoma treated with postoperative hyperthermic intraperitoneal...

Ovarian carcinosarcoma (OCS) is a rare and highly aggressive malignancy with no established standard treatment and a poor prognosis. This case describes sustained disease control achieved through the combination of cytoreductive surgery followed by postoperative hyperthermic intraperitoneal chemotherapy (postoperative HIPEC) and molecularly guided sequential maintenance therapy.

We report the clinicopathological features, diagnosis, and treatment of a 60-year-old woman with advanced OCS. After cytoreductive surgery, she received postoperative HIPEC followed by adjuvant chemotherapy nab-paclitaxel and carboplatin, then sequential maintenance therapy with bevacizumab followed by olaparib based on homologous recombination deficiency (HRD) positivity. Relevant literature on OCS management was reviewed.

The patient remained progression-free with good performance status at 24 months of follow-up.

This hypothesis-generating case suggests that for selected patients with OCS, a multimodal approach incorporating aggressive cytoreductive surgery, postoperative HIPEC, and HRD-guided sequential maintenance therapy may warrant further investigation.